Akebia Saponin D attenuates amyloid β-induced cognitive deficits and inflammatory response in rats: Involvement of Akt/NF-κB pathway

Behavioural Brain Research

Volumn 235, Issue 2, 2012, Pages 200-209

  Yu, Xing ^a   Wang, Lin Na ^a   Du, Qian Ming ^a   Ma, Lin ^a   Chen, Li ^a   You, Ran ^a   Liu, Ling ^a   Ling, Jing Jing ^a   Yang, Zhong Lin ^a   Ji, Hui ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Akebia Saponin D (ASD); Akt NF B; Alzheimer's disease; Amyloid (A )1 42; Cognitive impairment; Inflammatory responses

Indexed keywords

AKEBIA SAPONIN D; AMYLOID BETA PROTEIN[1-42]; CYCLOOXYGENASE 2; HERBACEOUS AGENT; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; PROTEIN KINASE B; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BIOCHEMISTRY; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG STRUCTURE; HISTOCHEMISTRY; IN VIVO STUDY; LEARNING DISORDER; MALE; MAZE TEST; MEMORY DISORDER; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; RAT; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS;

AMYLOID BETA-PEPTIDES; ANIMALS; COGNITION DISORDERS; CYTOKINES; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION ROUTES; GENE EXPRESSION REGULATION; GLIAL FIBRILLARY ACIDIC PROTEIN; HIPPOCAMPUS; INFLAMMATION; MALE; MAZE LEARNING; NF-KAPPA B P52 SUBUNIT; ONCOGENE PROTEIN V-AKT; PEPTIDE FRAGMENTS; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; SAPONINS; SIGNAL TRANSDUCTION;

EID: 84865424133     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2012.07.045     Document Type: Article

References (81)

1. Selkoe D.J. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature 1999, 399:A23-A31.
2. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
3. Verdile G., Fuller S., Atwood C.S., Laws S.M., Gandy S.E., Martins R.N. The role of beta amyloid in Alzheimer's disease: still a cause of everything or the only one who got caught?. Pharmaceutical Research 2004, 50:397-409.
4. Giulian D., Haverkamp L.J., Li J., Karshin W.L., Yu J., Tom D., et al. Senile plaques stimulate microglia to release a neurotoxin found in Alzheimer brain. Neurochemistry International 1995, 27:119-137.
5. Klegeris A., Walker D.G., McGeer P.L. Interaction of Alzheimer beta-amyloid peptide with the human monocytic cell line THP-1 results in a protein kinase C-dependent secretion of tumor necrosis factor-alpha. Brain Research 1997, 747:114-121.
6. Combs C.K., Johnson D.E., Karlo J.C., Cannady S.B., Landreth G.E. Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPAR gamma agonists. Journal of Neuroscience 2000, 20:558-567.
7. Combs C.K. Inflammation and microglia actions in Alzheimer's disease. Journal of NeuroImmune Pharmacology 2009, 4:380-388.
8. Cameron B., Landreth G.E. Inflammation, microglia, and Alzheimer's disease. Neurobiology of Disease 2010, 37:503-509.
9. Lue L.F., Rydel R., Brigham E.F., Yang L.B., Hampel H., Murphy G.M., et al. Inflammatory repertoire of Alzheimer's disease and nondemented elderly microglia in vitro. Glia 2001, 35:72-79.
10. Kalaria R.N. Microglia and Alzheimer's disease. Current Opinion in Hematology 1999, 6:15-24.
11. Akiyama H., Barger S., Barnum S., Bradt B., Bauer J., Cole G.M., et al. Inflammation and Alzheimer's disease. Neurobiology of Aging 2000, 21:383-421.
12. Eikelenboom P., Veerhuis R., Scheper W., Rozemuller A.J., van Gool W.A., Hoozemans J.J. The significance of neuroinflammation in understanding Alzheimer's disease. Journal of Neural Transmission 2006, 113:1685-1695.
13. Hung T.M., Na M., Thuong P.T., Su N.D., Sok D., Song K.S., et al. Antioxidant activity of caffeoyl quinic acid derivatives from the roots of Dipsacus asper Wall. Journal of Eyhnopharmacology 2006, 108:188-192.
14. Ginty D.D., Bonni A., Greenberg M.E. Nerve growth factor activates a Ras-dependent protein kinase that stimulates c-fos transcription via phosphorylation of CREB. Cell 1994, 77:713-725.
15. Suh H., Song D., Huh S., Son K., Kim Y. Antinociceptive mechanisms of Dipsacus saponin C administered intrathecally in mice. Journal of Ethnopharmacology 2000, 71:211-218.
16. Zhou Y.Q., Yang Z.L., Xu L., Li P., Hu Y.Z., Akebia Saponin D. a saponin component from Dipsacus asper Wall, protects PC 12 cells against amyloid-beta induced cytotoxicity. Cell Biology International 2009, 33:1102-1110.
17. Wei W., Wang X., Kusiak J.W. Signaling events in amyloid beta-peptide-induced neuronal death and insulin-like growth factor I protection. Journal of Biological Chemistry 2002, 277:17649-17656.
18. Delobette S., Privat A., Maurice T. In vitro aggregation facilities beta-amyloid peptide-(25-35)-induced amnesia in the rat. European Journal of Pharmacology 1997, 319:1-4.
19. Pike C.J., Burdick D., Walencewicz A.J., Glabe C.G., Cotman C.W. Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state. Journal of Neuroscience 1993, 13:1676-1687.
20. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 2007, Academic Press/Elsevier, Amsterdam, Boston. 6th ed.
21. Yu X., Wang L.N., Ma L., You R., Cui R., Ji D., et al. Akebia saponin D attenuates ibotenic acid-induced cognitive deficits and pro-apoptotic response in rats: involvement of MAPK signal pathway. Pharmacology Biochemistry and Behavior 2012, 101:479-486.
22. Geng Y., Li C., Liu J., Xing G., Zhou L., Dong M., et al. Beta-asarone improves cognitive function by suppressing neuronal apoptosis in the beta-amyloid hippocampus injection rats. Biological and Pharmaceutical Bulletin 2010, 33:836-843.
23. Ji C., Li Q., Aisa H., Yang N., Dong Y.L., Liu Y.Y., et al. Gossypium herbaceam extracts attenuate ibotenic acid-induced excitotoxicity in rat hippocampus. Journal of Alzheimers Disease 2009, 16:331-339.
24. Mueller S.C., Temple V., Oh E., VanRyzin C., Williams A., Cornwell B., et al. Early androgen exposure modulates spatial cognition in congenital adrenal hyperplasia (CAH). Psychoneuroendocrinology 2008, 33:973-980.
25. Kwon S.H., Lee H.K., Kim J.A., Hong S.I., Kim S.Y., Jo T.H., et al. Neuroprotective effects of Eucommia ulmoides Oliv. Bark on amyloid beta(25-35)-induced learning and memory impairments in mice. Neuroscience Letters 2011, 487:123-127.
26. Wolthuis O.L. Behavioural effects of etiracetam in rats. Pharmacology Biochemistry and Behavior 1981, 15:247-255.
27. Conrad C.D., Galea L.A., Kuroda Y., McEwen B.S. Chronic stress impairs rat spatial memory on the Y maze, and this effect is blocked by tianeptine pretreatment. Behavioral Neuroscience 1996, 110:1321-1334.
28. Malm T., Ort M., Tahtivaara L., Jukarainen N., Goldsteins G., Puolivali J., et al. beta-Amyloid infusion results in delayed and age-dependent learning deficits without role of inflammation or beta-amyloid deposits. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:8852-8857.
29. Vollmar P., Kullmann J.S., Thilo B., Claussen M.C., Rothhammer V., Jacobi H., et al. Active immunization with amyloid-beta 1-42 impairs memory performance through TLR2/4-dependent activation of the innate immune system. Journal of Immunology 2010, 185:6338-6347.
30. Di Bona D., Scapagnini G., Candore G., Castiglia L., Colonna-Romano G., Duro G., et al. Immune-inflammatory responses and oxidative stress in Alzheimer's disease: therapeutic implications. Current Pharmaceutical Design 2010, 16:684-691.
31. Abdi A., Sadraie H., Dargahi L., Khalaj L., Ahmadiani A. Apoptosis inhibition can be threatening in Abeta-induced neuroinflammation, through promoting cell proliferation. Neurochemical Research 2011, 36:39-48.
32. Koriyama Y., Chiba K., Mohri T. Propentofylline protects beta-amyloid protein-induced apoptosis in cultured rat hippocampal neurons. European Journal of Pharmacology 2003, 458:235-241.
33. Mattson M.P. Pathways towards and away from Alzheimer's disease. Nature 2004, 430:631-639.
34. Janus C., Pearson J., McLaurin J., Mathews P.M., Jiang Y., Schmidt S.D., et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000, 408:979-982.
35. Christensen R., Marcussen A.B., Wortwein G., Knudsen G.M., Aznar S. Abeta(1-42) injection causes memory impairment, lowered cortical and serum BDNF levels, and decreased hippocampal 5-HT(2A) levels. Experimental Neurology 2008, 210:164-171.
36. Yamada K., Tanaka T., Han D., Senzaki K., Kameyama T., Nabeshima T. Protective effects of idebenone and alpha-tocopherol on beta-amyloid-(1-42)-induced learning and memory deficits in rats: implication of oxidative stress in beta-amyloid-induced neurotoxicity in vivo. European Journal of Neuroscience 1999, 11:83-90.
37. Itagaki S., McGeer P.L., Akiyama H., Zhu S., Selkoe D. Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. Journal of Neuroimmunology 1989, 24:173-182.
38. Miyazono M., Iwaki T., Kitamoto T., Kaneko Y., Doh-ura K., Tateishi J. A comparative immunohistochemical study of Kuru and senile plaques with a special reference to glial reactions at various stages of amyloid plaque formation. American Journal of Pathology 1991, 139:589-598.
39. Eikelenboom P., Bate C., Van Gool W.A., Hoozemans J.J., Rozemuller J.M., Veerhuis R., et al. Neuroinflammation in Alzheimer's disease and prion disease. Glia 2002, 40:232-239.
40. Gonzalez-Scarano F., Baltuch G. Microglia as mediators of inflammatory and degenerative diseases. Annual Review of Neuroscience 1999, 22:219-240.
41. Perry V.H., Nicoll J.A., Holmes C. Microglia in neurodegenerative disease. Nature Reviews Neuroscience 2010, 6:193-201.
42. Kreutzberg G.W. Microglia: a sensor for pathological events in the CNS. Trends in Neurosciences 1996, 19:312-318.
43. Gao H.M., Hong J.S. Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. Trends in Immunology 2008, 29:357-365.
44. Floden A.M., Combs C.K. Beta-amyloid stimulates murine postnatal and adult microglia cultures in a unique manner. Journal of Neuroscience 2006, 26:4644-4648.
45. Luo J., Lang J.A., Miller M.W. Transforming growth factor beta1 regulates the expression of cyclooxygenase in cultured cortical astrocytes and neurons. Journal of Neurochemistry 1998, 71:526-534.
46. Cheng G., Whitehead S.N., Hachinski V., Cechetto D.F. Effects of pyrrolidine dithiocarbamate on beta-amyloid(25-35)-induced inflammatory responses and memory deficits in the rat. Neurobiology of Disease 2006, 23:140-151.
47. Cacabelos R., Alvarez X.A., Fernandez-Novoa L., Franco A., Mangues R., Pellicer A., et al. Brain interleukin-1 beta in Alzheimer's disease and vascular dementia. Methods and Findings in Experimental and Clinical Pharmacology 1994, 16:141-151.
48. McGeer P.L., Rogers J., McGeer E.G. Neuroimmune mechanisms in Alzheimer disease pathogenesis. Alzheimer Disease and Associated Disorders 1994, 8:149-158.
49. Lee K.S., Chung J.H., Choi T.K., Suh S.Y., Oh B.H., Hong C.H. Peripheral cytokines and chemokines in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders 2009, 28:281-287.
50. Olson L., Humpel C. Growth factors and cytokines/chemokines as surrogate biomarkers in cerebrospinal fluid and blood for diagnosing Alzheimer's disease and mild cognitive impairment. Experimental Gerontology 2010, 45:41-46.
51. Heneka M.T., O'Banion M.K. Inflammatory processes in Alzheimer's disease. Journal of Neuroimmunology 2007, 184:69-91.
52. Bales K.R., Du Y., Dodel R.C., Yan G.M., Hamilton-Byrd E., Paul S.M. The NF-κB/Rel family of proteins mediates Abeta-induced neurotoxicity and glial activation. Brain Research Molecular Brain Research 1998, 57:63-72.
53. Meda L., Cassatella M.A., Szendrei G.I., Otvos L., Baron P., Villalba M., et al. Activation of microglial cells by beta-amyloid protein and interferon-gamma. Nature 1995, 374:647-650.
54. Liu M.H., Lin Y.S., Sheu S.Y., Sun J.S. Anti-inflammatory effects of daidzein on primary astroglial cell culture. Nutritional Neuroscience 2009, 12:123-134.
55. Hayden M.S., Ghosh S. Signaling to NF-κB. Genes and Development 2004, 18:2195-2224.
56. Zandi E., Rothwarf D.M., Delhase M., Hayakawa M., Karin M. The IκB kinase complex (IKK) contains two kinase subunits. IKKalpha and IKKbeta, necessary for IκB phosphorylation and NF-κB activation. Cell 1997, 91:243-252.
57. Tusi S.K., Ansari N., Amini M., Amirabad A.D., Shafiee A., Khodagholi F. Attenuation of NF-κB and activation of Nrf2 signaling by 1,2,4-triazine derivatives, protects neuron-like PC12 cells against apoptosis. Apoptosis 2010, 15:738-751.
58. Lawrence T., Gilroy D.W., Colville-Nash P.R., Willoughby D.A. Possible new role for NF-κB in the resolution of inflammation. Nature Medicine 2001, 7:1291-1297.
59. Dimmeler S., Breitschopf K., Haendeler J., Zeiher A.M. Dephosphorylation targets Bcl-2 for ubiquitin-dependent degradation: a link between the apoptosome and the proteasome pathway. Journal of Experimental Medicine 1999, 189:1815-1822.
60. Li B., Dou Q.P. Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:3850-3855.
61. Borner C. The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions. Molecular Immunology 2003, 39:615-647.
62. Korsmeyer S.J. Bcl-2: a repressor of lymphocyte death. Immunology Today 1992, 13:285-288.
63. Datta S.R., Dudek H., Tao X., Masters S., Fu H., Gotoh Y., et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997, 91:231-241.
64. Yoshimoto T., Uchino H., He Q.P., Li P.A., Siesjo B.K. Cyclosporin A, but not FK506, prevents the downregulation of phosphorylated Akt after transient focal ischemia in the rat. Brain Research 2001, 899:148-158.
65. Rickle A., Bogdanovic N., Volkman I., Winblad B., Ravid R., Cowburn R.F. Akt activity in Alzheimer's disease and other neurodegenerative disorders. Neuroreport 2004, 15:955-959.
66. Ho L., Qin W., Pompl P.N., Xiang Z., Wang J., Zhao Z., et al. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB Journal 2004, 18:902-904.
67. Martin D., Salinas M., Lopez-Valdaliso R., Serrano E., Recuero M., Cuadrado A. Effect of the Alzheimer amyloid fragment Abeta(25-35) on Akt/PKB kinase and survival of PC12 cells. Journal of Neurochemistry 2001, 78:1000-1008.
68. Frozza R.L., Horn A.P., Hoppe J.B., Simao F., Gerhardt D., Comiran R.A., et al. A comparative study of beta-amyloid peptides Abeta1-42 and Abeta25-35 toxicity in organotypic hippocampal slice cultures. Neurochemical Research 2009, 34:295-303.
69. Matsuzaki K., Yamakuni T., Hashimoto M., Haque A.M., Shido O., Mimaki Y., et al. Nobiletin restoring beta-amyloid-impaired CREB phosphorylation rescues memory deterioration in Alzheimer's disease model rats. Neuroscience Letters 2006, 400:230-234.
70. Ito S., Sawada M., Haneda M., Ishida Y., Isobe K. Amyloid-beta peptides induce several chemokine mRNA expressions in the primary microglia and Ra2 cell line via the PI3K/Akt and/or ERK pathway. Neuroscience Reasearch 2006, 56:294-299.
71. Ozes O.N., Mayo L.D., Gustin J.A., Pfeffer S.R., Pfeffer L.M., Donner D.B. NF-κB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 1999, 401:82-85.
72. Sizemore N., Lerner N., Dombrowski N., Sakurai H., Stark G.R. Distinct roles of the Iκ B kinase alpha and beta subunits in liberating nuclear factor κ B (NF-κB) from IκB and in phosphorylating the p65 subunit of NF-κB. Journal of Biological Chemistry 2002, 277:3863-3869.
73. Madrid L.V., Mayo M.W., Reuther J.Y., Baldwin A.S. Akt stimulates the transactivation potential of the RelA/p65 subunit of NF-κB through utilization of the Iκ B kinase and activation of the mitogen-activated protein kinase p38. Journal of Biological Chemistry 2001, 276:18934-18940.
74. Shintani E.Y., Uchida K.M. Donepezil: an anticholinesterase inhibitor for Alzheimer's disease. American Journal of Health-System Pharmacy 1997, 54:2805-2810.
75. Jones R., Sheehan B., Phillips P., Juszczak E., Adams J., Baldwin A., et al. DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT. Trials 2009, 10:57.
76. Tayeb H.O., Yang H.D., Price B.H., Tarazi F.I. Pharmacotherapies for Alzheimer's disease: beyond cholinesterase inhibitors. Pharmacology and Therapeutics 2012, 134:8-25.
77. Xia Z., Zhang R., Wu P., Hu Y. Memory defect induced by beta-amyloid plus glutamate receptor agonist is alleviated by catalpol and donepezil through different mechanisms. Brain Research 2012, 1441:27-37.
78. Furukawa-Hibi Y., Alkam T., Nitta A., Matsuyama A., Mizoguchi H., Suzuki K., et al. Butyrylcholinesterase inhibitors ameliorate cognitive dysfunction induced by amyloid-beta peptide in mice. Behavioural Brain Research 2011, 225:222-229.
79. De Bartolo P., Gelfo F., Mandolesi L., Foti F., Cutuli D., Petrosini L. Effects of chronic donepezil treatment and cholinergic deafferentation on parietal pyramidal neuron morphology. Journal of Alzheimers Disease 2009, 17:177-191.
80. Haug K.H., Bogen I.L., Osmundsen H., Walaas I., Fonnum F. Effects on cholinergic markers in rat brain and blood after short and prolonged administration of donepezil. Neurochemical Research 2005, 30:1511-1520.
81. Hernandez C.M., Gearhart D.A., Parikh V., Hohnadel E.J., Davis L.W., Middlemore M.L., et al. Comparison of galantamine and donepezil for effects on nerve growth factor, cholinergic markers, and memory performance in aged rats. Journal of Pharmacology and Experimental Therapeutics 2006, 316:679-694.